Prolonged remission maintenance in acute myeloid leukaemia.
Twenty-five patients with acute myeloid leukaemia were treated with three quadruple drug combinations in predetermined rotation: TRAP (thioguanine, daunorubicin, cytarabine, prednisolone); COAP (cyclophosphamide, vincristine, cytarabine, prednisolone); and POMP (prednisolone, vincristine, methotrexate, mercaptopurine). Fifteen patients (60%) achieved complete remission and five (20%) partial remission. For maintenance, five-day courses of drugs were administered every 14 to 21 days and doses were increased to tolerance. The median length of complete remission was 66 weeks. In eight patients remission maintenance treatment was discontinued and some remained in complete remission for over two years. In this series the remission induction rate was comparable with that reported for other regimens and complete remission lasted longer with this intensive maintenance regimen than with others. Nevertheless, the TRAP programme must still be regarded as only palliative treatment for acute myeloid leukaemia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D013866:Thioguanine; D008727:Methotrexate; D003630:Daunorubicin
Br J Cancer. 1977 Mar;35(3):265-72
322689
Cancer. 1971 Feb;27(2):247-56
5100389
Arch Intern Med. 1976 Nov;136(11):1256-61
984987
Lancet. 1974 Dec 14;2(7894):1405-9
4140327
Lancet. 1969 Feb 15;1(7590):330-3
4179349
Lancet. 1975 Oct 4;2(7936):621-4
52000
Semin Hematol. 1972 Apr;9(2):181-91
4553226
Cancer. 1972 Dec;30(6):1572-82
4509106
Br Med J. 1973 Jan 20;1(5846):131-7
4513355
Br Med J. 1970 Nov 28;4(5734):513-7
4921703
JAMA. 1971 Apr 26;216(4):648-52
5279904
Medicine (Baltimore). 1970 Nov;49(6):505-13
5286084
Clin Pharmacol Ther. 1971 Jul-Aug;12(4):599-606
5284835
Cancer. 1975 Aug;36(2):775-95
1057450
Arch Intern Med. 1976 Dec;136(12):1417-21
793554